Evaluation of Safety, Efficacy and Pharmacodynamic Effect of Bertilimumab in Patients With Bullous Pemphigoid

• ClinicalTrials.gov Identifier: NCT02226146
• Recruitment Status: Completed
• First Posted: August 27, 2014
• Last Update Posted: May 23, 2018
• Sponsor: Immune Pharmaceuticals
• Information provided by (Responsible Party): Immune Pharmaceuticals

Tracking Information

• First Submitted Date: July 27, 2014
• First Posted Date: August 27, 2014
• Last Update Posted Date: May 23, 2018
• Actual Study Start Date: February 2016
• Actual Primary Completion Date: April 2018 (Final data collection date for primary outcome measure)

Current Primary Outcome Measures (submitted: May 21, 2018)

Safety Endpoints [ Time Frame: Participants will be followed for the duration of the study , an expected average of 118 days ]

Safety outcome would be assessed as the number of the following events which the participants experienced throughout the study:

• Number if Adverse events (AE)
• Injection site reactions after infusions
• Abnormal Physical findings during the examination
• Abnormal Vital signs (blood pressure, heart rate, temperature)
• Abnormal ECG
• Number of Concomitant medications taken
• Abnormal Laboratory values
• Development of anti-bertilimumab antibodies

Original Primary Outcome Measures (submitted: August 26, 2014)

• Safety Measurements [ Time Frame: participants will be followed for the duration of the study , an expected average of 60 days ]
  Safety outcome would be assessed as the number of the following events which the participants experienced throughout the study:

  • Number if Adverse events (AE)
  • Injection site reactions after infusions
  • Abnormal Physical findings during the examination
  • Abnormal Vital signs (blood pressure, heart rate, temperature)
  • Abnormal ECG
  • Number of Concomitant medications taken
  • Abnormal Laboratory values
• Efficacy [ Time Frame: participants will be followed for the duration of the study , an expected average of 60 day ]
  Number of patients which achieved a reduction in BP Disease Area Index (BPDAI questionnaire) score, of at least 50%, 75% and 90%.
• Efficacy [ Time Frame: participants will be followed for the duration of the study , an expected average of 60 day ]
  Number of patients which decrease to prednisone dose of ≤ 10mg/day

Current Secondary Outcome Measures (submitted: May 21, 2018)

• Efficacy Endpoint: Change in Bullous Pemphigoid Disease Area Index (BPDAI) [ Time Frame: Participants will be followed for the duration of the study, an expected average of 84 days ]
  The BPDAI is a validated measure of bullous pemphigoid disease activity consisting of four subscores: skin blistering (0-120), uricaria (0-120), mucosal blistering (0-120) and damage/pigmentation (0-12). The activity score consists of the first three subscored (0-360) • Change in BPDAI Activity Score at each scheduled measurement timepoint
• Efficacy Endpoint: BPDAI responders [ Time Frame: Participants will be followed for the duration of the study, an expected average of 84 days ]
  • Proportion of subjects who achieve a reduction in BPDAI Activity Score of at least 50%, 75% and 90% at Days 42, 56, 70 or 84
• Efficacy Endpoint: Prednisone dose [ Time Frame: Participants will be followed for the duration of the study, an expected average of 84 days ]
  • Proportion of subjects who have tapered to prednisone dose of ≤10 mg/day at at Days 42, 56, 70 or 84
• Efficacy Endpoint: Change in BPDAI pruritus component [ Time Frame: Participants will be followed for the duration of the study, an expected average of 84 days ]
  • Change in pruritus visual analog scale (the sum of three 0-10 pruritus assessments: pruritus intensity over the prior day, week and month) at each scheduled measurement timepoint
• Efficacy Endpoint: Change in Autoimmune Bullous Disease Quality of Life (ABQOL) [ Time Frame: Participants will be followed for the duration of the study, an expected average of 84 days ]
  The ABQOL questionnaire is a validated 17 item questionnaire (range 0-51) assessing quality of life in patients with autoimmune blistering diseases • ABQOL assessed at each scheduled measurement timepoint
• Efficacy Endpoint: Control of disease activity [ Time Frame: Participants will be followed for the duration of the study, an expected average of 84 days ]
  Control of disease activity is defined as the time when at least two of the following occur: new lesions cease to form, established lesions begin to heal and/or pruritic symptoms start to abate. • Mean time from baseline to control of disease activity

Original Secondary Outcome Measures (submitted: August 26, 2014)

• Efficacy Measurements [ Time Frame: participants will be followed for the duration of the study , an expected average of 60 day ]
  • Number of patients who achieve control of disease activity untill visit 5 (Defined as a state in which new lesions cease to form and established lesions begin to heal and pruritic symptoms start to abate).
  • Mean time to control of disease activity (Defined as the time from baseline at which new lesions cease to form and established lesions begin to heal and pruritic symptoms start to abate).
  • Changes in BP Disease Area Index questionnaire score
  • Changes in pruritus visual analogue questionnaire score
  • Changes in Quality of life questionnaire score at each scheduled
• PHARMACODYNAMIC Measurements [ Time Frame: participants will be followed for the duration of the study , an expected average of 60 day ]
  PD measurements will be assessed through:

  • Changes in the titers of BP180 and BP230 autoantibody
  • Changes in the amount of eosinophils counted in the blood.

Current Other Pre-specified Outcome Measures (submitted: May 21, 2018)

• Pharmacokinetic (PK) Endpoints - Cmax [ Time Frame: Participants will be followed the duration of the study, an expected average of 84 days ]
  • PK analysis for bertilimumab concentration: blood samples will be collected on dosing days (pre-dose, and at 30 minutes and 4 hours following initiation of study drug infusion) and once at remaining study visits (excluding screening). The following PK parameters will be calculated, to the degree possible given the number of timepoints: Cmax, Tmax, AUC, Vdist and t1/2. Additional standard and exploratory PK parameters will be calculated if deemed necessary. Cmax is the maximum bertilimumab serum concentration observed.
• Pharmacokinetic (PK) Endpoints - Tmax [ Time Frame: Participants will be followed the duration of the study, an expected average of 84 days ]
  • Tmax is the time until Cmax
• Pharmacokinetic (PK) Endpoints - AUC [ Time Frame: Participants will be followed the duration of the study, an expected average of 84 days ]
  • AUC is the area under the curve
• Pharmacokinetic (PK) Endpoints - Vdist [ Time Frame: Participants will be followed the duration of the study, an expected average of 84 days ]
  • Vdist is the volume of ditribution
• Pharmacokinetic (PK) Endpoints - T1/2 [ Time Frame: Participants will be followed the duration of the study, an expected average of 84 days ]
  • T1/2 is the elimination half life
• Pharmacodynamic Endpoint: Change in autoantibody titres [ Time Frame: Participants will be followed the duration of the study, an expected average of 84 days ]
  • Change in BP180 and BP230 autoantibody titres at each scheduled sampling timepoint compared to baseline
• Pharmacodynamic Endpoint: Change in blood eosinophil count [ Time Frame: Participants will be followed the duration of the study, an expected average of 84 days ]
  • Change in blood eosinophil count at each scheduled sampling timepoint compared to baseline
• Pharmacodynamic Endpoint: Change in tissue eosinophil count [ Time Frame: Participants will be followed the duration of the study, an expected average of 84 days ]
  • Change in tissue eosinophil count assessed on biopsy at the scheduled timepoint compared to screening
• Pharmacodynamic Endpoint: Change in serum eotaxin-1 level [ Time Frame: Participants will be followed the duration of the study, an expected average of 84 days ]
  • Change in serum eotaxin-1 level at each scheduled sampling timepoint compared to baseline
• Exploratory Endpoint: Change in biomarkers [ Time Frame: Participants will be followed the duration of the study, an expected average of 84 days ]
  • Change in PBMC biomarkers at each scheduled timepoint compared to baseline, including but not limited to: CD4, CD25, CD8, CD69, CD62L, CCR3 and Foxp3 via flow cytometry analyses.
  • Change in Eosinophil Cationic Protein serum levels

• Original Other Pre-specified Outcome Measures: Not Provided

Descriptive Information

• Brief Title: Evaluation of Safety, Efficacy and Pharmacodynamic Effect of Bertilimumab in Patients With Bullous Pemphigoid
• Official Title: An Open-Label, Proof of Concept Study Designed to Evaluate the Safety, Efficacy and Pharmacodynamic Effect of Bertilimumab in Patients With Newly Diagnosed, Moderate to Extensive Bullous Pemphigoid

Brief Summary

This is an open-label, proof-of-concept, single group study in adult patients with newly diagnosed, moderate to extensive BP.

The study will consist of three periods: a screening period of up to 2 weeks, an open-label treatment period lasting 4 weeks consisting of IV infusion of bertilimumab on Days 0 and 14 and 28, and a safety and efficacy follow-up period of approximately 13 weeks.

Patients will receive concomitant oral steroids during the treatment and follow-up period.

Detailed Description

This is an open-label, proof-of-concept, single group study in adult patients with newly diagnosed, moderate to extensive BP.

The study will consist of three periods: a screening period of up to 2 weeks, an open-label treatment period lasting 4 weeks consisting of IV infusion of bertilimumab on Days 0 and 14 and Day 28, and a safety and efficacy follow-up period of approximately 13 weeks.

Patients will receive concomitant oral steroids during the treatment and follow-up period. They will start on 30 mg prednisone daily (or equivalent). The initial dose will be maintained for at least 1 week, commencing on Day 0, until blister formation has ceased, crusts and erosions have disappeared and reepithelialization of lesions has started. The corticosteroid dose will then be reduced to 20 mg daily for 5 to 14 days. According to clinical response, this will be followed by corticosteroid dose reduction in 5 mg steps every 5 to 14 days until a dose of 10 mg daily is reached and then corticosteroid dose reduction in 2.5 mg steps every 5 to 14 days until the end of the study.

• Study Type: Interventional
• Study Phase: Phase 2
• Study Design: Allocation: N/A; Intervention Model: Single Group Assignment; Masking: None (Open Label); Primary Purpose: Treatment
• Condition: Pemphigoid, Bullous
• Intervention: Biological: Bertilimumab

Study Arms

Experimental: Bertilimumab

Intravenous injection over 30 minutes of 10 mg/kg of Bertilimumab in physiological solution (PBS)

Intervention: Biological: Bertilimumab

• Publications *: Not Provided

Recruitment Information

• Recruitment Status: Completed
• Actual Enrollment (submitted: May 21, 2018): 11
• Original Estimated Enrollment (submitted: August 26, 2014): 15
• Actual Study Completion Date: April 2018
• Actual Primary Completion Date: April 2018 (Final data collection date for primary outcome measure)

Eligibility Criteria

Inclusion Criteria:

1. Males or females, ≥ 60 years of age.
2. Karnofsky performance status > 60%

3. Newly diagnosed, Bullous Pemphigoid per standard diagnostic criteria:

   • Clinical presentation [2]
   • Skin biopsy from a fresh blister showing subepidermal clefting and an inflammatory infiltrate consisting mainly of eosinophils
   • Immunofluorescence (IF) studies performed on uninvolved skin collected approximately 1 cm away from a fresh blister showing linear deposition of IgG and/or C3 along the basement membrane zone.
4. Moderate to extensive Bullous Pemphigoid defined by the mean number of new bullae and urticarial plaques that have appeared over the course of 3 days as determined by the investigator or referring physician (moderate disease defined by > 1 and ≤ 10 new bullae daily and ≥ 5 urticarial plaques and extensive disease by >10 new bullae daily) [3].
5. Adequate cardiac, renal and hepatic function as determined by the Investigator and demonstrated by screening laboratory evaluations, vital sign measurement, ECG recording and physical examination results.
6. Females of childbearing potential must agree to use effective contraception consistently throughout the study (such as hormonal contraception or two forms of barrier contraception) and have a negative serum pregnancy test at screening and a negative urine pregnancy test per the schedule of visits. Women are considered post-menopausal and not of childbearing potential if they have had 12 months of amenorrhea or have had surgical bilateral oophorectomy (with or without hysterectomy) or tubal ligation at least six weeks previously.
7. Males must have had a vasectomy or have expressed that they have no interest in fertility in the future.
8. Fertile males must agree to use effective contraception consistently throughout the study and for a period of four months following the end of study drug administration.
9. Willing and able to adhere to the study visit schedule and other protocol requirements.
10. Willing and able to provide voluntary written informed consent or written informed consent from a legally authorized representative with assent from the patient.

Exclusion criteria:

1. Patients with severe medical or surgical conditions at screening or baseline including, but not limited to, severe dementia or mental impairment, severe stroke, severe cardiac insufficiency, severe arterial hypertension, severe or uncontrolled renal, hepatic, hematological, gastrointestinal, endocrine, pulmonary, cardiac, neurologic, cerebral, psychiatric, or any other severe acute or chronic medical condition that may increase the risk associated with study participation/treatment or may interfere with the interpretation of study results and, in the Investigator's opinion, would make the patient inappropriate for study entry.
2. Presence of any malignancy that has been under active treatment (e.g., radiotherapy or chemotherapy) within the 2 years prior to baseline or is anticipated to require treatment during the study period (including follow up) with the exception of patients with removal of uncomplicated basal cell carcinoma or cutaneous squamous cell carcinoma, who may take part in the study.
3. Congenital or acquired immunodeficiency (e.g., common variable immunodeficiency, organ transplantation).
4. Clinically significant vital sign measurements or ECG findings as determined by the Investigator.

5. Clinically significant abnormal laboratory test results, unless regarded by the Investigator as related to BP, including but not limited to:

   • Hemoglobin level <10.0 g/dL
   • White blood cell count < 3 x 103/μL
   • Lymphocyte count < 0.5 x 103/μL
   • Platelet count <100 x 103/μL or >1200 x 103/μL
   • Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) >3 the upper limit of normal (ULN)
   • Alkaline phosphatase >3 ULN
   • Serum creatinine >2 ULN
6. Patients with mild, relapsed or refractory Bullous Pemphigoid. Mild disease defined by the mean number of new lesions that have appeared over the course of 3 days as determined by the investigator or referring physician, as follows: ≤ 1 bulla or < 5 urticarial plaques.
7. Concomitant skin conditions preventing physical evaluation of Bullous Pemphigoid.
8. Active or recent history of clinically significant infection within 1 month of baseline.
9. Pregnant or breast-feeding, or planning to become pregnant during the study.
10. Participation in a clinical trial of an investigational (unapproved) product within 4 weeks of baseline.
11. Known hypersensitivity to bertilimumab or any of the drug excipients.
12. Use of prednisone or other systemic steroids (excluding inhaled or ocular use of steroids) within 4 weeks prior to baseline. (Concomitant oral corticosteroids administered as part of the study protocol, from Day 0 onward, are allowed). Use of class 1 and 2 topical steroids (such as clobetasol propionate cream, reference Appendix D for further guidance) within 4 weeks prior to baseline. (Use of other topical steroids is allowed throughout the study at the discretion of the investigator).
13. Treatment with immunosuppressants (e.g., azathioprine, methotrexate) within 4 weeks prior to baseline.
14. Treatment with biologics (e.g., etanercept, adalimumab, ustekinumab, infliximab, intravenous Ig) within 4 months of baseline. Patients who have received rituximab within 1 year of baseline will be excluded from study participation.
15. Treatment with macrolides or tetracyclines within 4 weeks prior to baseline.
16. Received a vaccine or other immunostimulator within 4 weeks prior to baseline. Subject has current clinical, radiographic or laboratory evidence of active mycobacterium tuberculosis (TB) infection or prior evidence of active TB that, in the opinion of the investigator, has not been adequately treated or controlled and that represents a reactivation risk. If in the investigator's opinion the patient is at risk for latent TB, the patient should be evaluated for active/latent TB as applicable (e.g. PPD, QFT, and/or chest x-ray).

18. Evidence of an active disease of hepatitis B (HBsAg positive or HBcAb positive) or hepatitis C (HCV ab positive), CMV (IgM positive) or human immunodeficiency virus (HIV) infection (HIV1/2 Ab positive 19. Active abuse of alcohol or drugs. 20. Any other condition, which in the opinion of the Investigator would place the patient at an unacceptable risk if participating in the study protocol.

Sex/Gender

• Sexes Eligible for Study: All

• Ages: 60 Years and older (Adult, Older Adult)
• Accepts Healthy Volunteers: No
• Contacts: Contact information is only displayed when the study is recruiting subjects
• Listed Location Countries: Israel, United States

Administrative Information

• NCT Number: NCT02226146
• Other Study ID Numbers: Immune/BRT/BP-01
• Has Data Monitoring Committee: No
• U.S. FDA-regulated Product: Not Provided
• IPD Sharing Statement: Not Provided
• Current Responsible Party: Immune Pharmaceuticals
• Original Responsible Party: Same as current
• Current Study Sponsor: Immune Pharmaceuticals
• Original Study Sponsor: Same as current
• Collaborators: Not Provided

Investigators

• Principal Investigator: Eli Sprecher, MD; Sourasky-Ichilov Tel Aviv Medical Center

• PRS Account: Immune Pharmaceuticals
• Verification Date: May 2018